Novel Nanogel Drug Delivery System to Undergo Preliminary Clinical Trials

The cocktail, which was designed to treat metastatic cancers, comprises two agents, interleukin-2 (IL-2) and an inhibitor of tissue growth factor beta (TGF-beta). IL-2 amplifies the body’s immune system, while the TGF-beta inhibitor dampens the cancer cells’ ability to hide from the immune system.

The biopharmaceutical company Modulate Therapeutics Inc. (Tampa, FL, USA) has secured the rights to bring the drug delivery system to the clinical proof-of-concept stage.

Developer of the nanogel system, Dr. Terek Fahmy, associate professor of biomedical engineering at Yale University, said, "The delivery system is a kind of rational therapy, in that it fuses established biological and clinical findings to the emerging field of nanotechnology. It creates a new solution that could potentially deal a significant blow to cancer and even autoimmune disease in future applications."

Related Links:
Yale University
Modulate Therapeutics